Market closedNon-fractional

Celcuity/CELC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Celcuity

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Ticker

CELC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Minneapolis, United States

Employees

55

Celcuity Metrics

BasicAdvanced
$573M
Market cap
-
P/E ratio
-$2.75
EPS
0.87
Beta
-
Dividend rate
$573M
0.87
11.232
10.641
28.226
28.362
-13.89%
-26.97%
-57.17%
3.76
3.76
-7.473
5.58%
42.27%

What the Analysts think about Celcuity

Analyst Ratings

Majority rating from 6 analysts.
Buy

Celcuity Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
14.89%
Profit margin
0.00%
NaN%

Celcuity Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.65%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.83
-$0.65
-$0.64
-
Expected
-$0.60
-$0.68
-$0.73
-$0.71
-$0.67
Surprise
10.46%
21.61%
-10.76%
-9.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Celcuity stock?

Celcuity (CELC) has a market cap of $573M as of July 05, 2024.

What is the P/E ratio for Celcuity stock?

The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of July 05, 2024.

Does Celcuity stock pay dividends?

No, Celcuity (CELC) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Celcuity dividend payment date?

Celcuity (CELC) stock does not pay dividends to its shareholders.

What is the beta indicator for Celcuity?

Celcuity (CELC) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Celcuity stock

Buy or sell Celcuity stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing